GE Healthcare Integrates Masimo's Pioneering SET Pulse Oximetry into Portrait Mobile Wearable Monitoring Platform

Nov 11, 2023 19:24 CST Updated 19:24

Masimo

Developer, Manufacturer, and Seller of Medical Monitoring Instruments

GE Healthcare

Digital Solution Provider

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

On November 8 local time, GE Healthcare and Masimo jointly announced an agreement:Integrate Masimo Signal Extraction Technology (SET) for pulse oximetry into GE Healthcare's recently approved Portrait Mobile wireless wearable monitoring system.

Portrait Mobile

According to reports,Portrait Mobile is the world's first wireless monitoring solution,Not only can it continuously monitor patients' vital signs in real time, providing reliable monitoring data for the care team, but it also offers patients more freedom and flexibility. In addition, it is an open Internet of Medical Things (IoMT) platform that utilizes the latest "cloud-native" technology to deliver an end-to-end experience for continuous monitoring with wearable devices.Received FDA 510(k) clearance in August this year, allowing it to be marketed in the United States.

This latest collaboration integrates Masimo SET pulse oximetry technology into the Portrait Mobile platform, enabling personalized, real-time, continuous monitoring of patients' vital signs while allowing them to remain mobile during critical recovery periods, particularly post-surgery or after discharge from the intensive care unit.Notably, this will enable clinicians to utilize Masimo's clinically validated Measure-through Motion and Low Perfusion™ oxygen saturation measurement technology to detect and continuously monitor changes in a patient’s status non-invasively.

Masimo SET

The StrongestPulse Oximetry Monitoring Technology

Currently,Masimo SET has been proven by more than 100 independent, objective studies and thousands of clinical evaluations, outperforming other pulse oximetry technologies under dynamic and low perfusion conditions;The use of SET for continuous monitoring in postoperative wards has also been shown to reduce deaths caused by opioid-induced respiratory depression, decrease rapid response team activations, and minimize transfers back to the intensive care unit.

In addition,The technology has also been proven to improve patient outcomes, assist clinicians in efficiently screening newborns for critical congenital heart disease (CCHD), reduce the incidence of severe retinopathy of prematurity (ROP) in preterm infants, decrease ventilator weaning time, and reduce arterial blood gas measurements in intensive care.Help healthcare professionals save newborn lives efficiently while reducing unnecessary costs associated with NICU admissions.

In fact,As early as 1995, Masimo launched the world's first pulse oximeter, MasimoSET®, capable of taking measurements during motion and low perfusion.At this time, Masimo, which had achieved both fame and profit, did not expand into other medical device fields but continued to focus on research in the direction of oxygen saturation monitoring.

So far,Globally, more than 200 million patients have used Masimo SET in leading hospitals and other healthcare settings worldwide.Masimo SET has also become the primary pulse oximetry technology for 9 of the top 10 hospitals in the 2021-22 U.S. News & World Report Best Hospitals Honor Roll.

This also brought丰厚的回报 to Masimo, enabling the company to successfully go public on NASDAQ in 2007.Even in the six years prior to 2021, Masimo maintained an average annual revenue growth of approximately 9%. In the past year of 2022, the company achieved a full-year revenue of $2.0358 billion with a growth rate of 10.6%. Currently, Masimo's valuation is as high as $4.415 billion.

Apple Wins Patent Case

Notably, Masimo recently won a lawsuit against Apple, successfully defending its patent for blood oxygen detection.

The feud between these two companies dates back to 2013.At that time, Apple Inc. successively hired Michael O’Reilly, Chief Medical Officer of Masimo, and Marcelo Lamego, Chief Technology Officer of Masimo's subsidiary Cercacor, to participate in the development of the Apple Watch.

Among them,Lamego only worked at Apple for six months, but during this time, he applied for 12 patents.And he has been listed as the inventor of several future patents by Apple. Moreover, the sensor development work he is engaged in at Apple is the same as what he did previously at Masimo.

In 2020,Masimo first sued Apple, claiming that Apple deliberately poached its employees, and accused Lamego of leaking Masimo's trade secrets to Apple.Claimed that Apple Watch infringed on its 10 patents.

In 2021, Masimo filed another lawsuit, specifically pointing out that the sixth-generation Apple Watch device infringed on its five patents related to blood oxygen measurement technology.Masimo Requests Ban on Apple Watch with Pulse Oximeter Function, Claims $3.1 Billion (Approx. 21.328 Billion RMB).

Then, in October 2022, Apple also launched a counterattack, accusing Masimo's WI series of smartwatches of infringing on several of its patents. Apple stated,It was during the previous litigation that Masimo Corporation "closely examined Apple's intellectual property" and obtained confidential information.

The five patents in the Masimo case,The Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office refused to review three of them and accepted two.This includes:

In January 2023, the U.S. International Trade Commission (ITC) ruled that Apple's Apple Watch with blood oxygen measurement functionality infringed on a pulse oximeter patent owned by medical technology company Masimo.In September, according to Reuters, Apple Inc. won in the U.S. Court of Appeals, upholding the ruling of the U.S. Patent Office court, which declared some patents of health monitoring company Masimo invalid.

October 26,The U.S. International Trade Commission (ITC) issued a limited exclusion order in a 337 investigation involving Apple Watch against Apple Inc., banning the import of the product into the United States.Before the ban takes effect, U.S. President Biden has 60 days to decide whether to overturn the ITC's decision.

Here, this three-year-long tug-of-war will temporarily come to an end. The partial ban on Apple Watch sales will also open up a significant market for Masimo's smartwatches.

Patient Monitor Market Landscape

The monitor is an instrument used to closely monitor and evaluate the patient's condition. In addition, it can also monitor the patient's treatment after medication and before surgery.The condition afterwards. Currently, the common types of monitors are mainly divided intoBedside monitors and telemetry monitors (also known as "ambulatory monitors"),Depending on the usage scenario, there are differences in the size and functions of the equipment.

A bedside monitor is an instrument placed next to the patient’s bed and connected to the patient, capable of continuously monitoring various physiological parameters or certain conditions of the patient, displaying alarms or recording data. It can also work as part of a system with a central monitoring station. On the other hand, a telemetry monitor is a small, portable electronic monitoring device that allows continuous monitoring of certain physiological parameters of a patient both inside and outside the hospital, enabling doctors to conduct non-real-time assessments.

Data shows,In 2016, the global (excluding Japan) patient monitoring device market size reached 2.68 billion US dollars. In 2018, the total value of the global vital signs monitoring device market reached 24.32 billion yuan, and it is expected to grow to 31.62 billion yuan by 2025, with a compound annual growth rate (CAGR) of 3.8%.

According to statistics from China's medical device industry,In 2016, the market size of China's patient monitor products was 1.75 billion yuan. Both the domestic and overseas monitoring markets maintained a steady growth trend, with the domestic market growing at approximately 15%, higher than the overseas growth rate of 4%.This shows that the overall scale of the patient monitor market is continuously expanding, and the market in China still has great development potential.

Currently, in the patient monitoring market, all medical device companies have their presence. Below are introductions to two well-known patient monitoring devices:

Philips

Philips IntelliVue MX800

In the global monitor market, Philips' monitoring business accounts for approximately 38% of the share.IntelliVue and SureSigns series of patient monitors provide flexible and convenient diagnosis and treatment with portable, compact, and dedicated models, meeting all monitoring environments, patient disease severity levels, and clinical requirements.

Notably, earlier this year and at mid-year, Philips expanded its partnership with Masimo on two occasions.Repeatedly integrating Masimo's technology with its own products to further capture market share.

Mindray Medical

Mindray mWear Wearable Monitor

Mindray ranks third in the global patient monitoring market with a market share of only 10%, compared toGE Healthcare, Philips Healthcare, and others still have room for further improvement. However, in the Chinese patient monitoring market, Mindray Medical is the absolute leader in the industry, with a market share of 64%, ranking first in the entire industry.

In May this year,Mindray, based on clinical pain points and rigid demands, innovatively developed the mWear wearable monitor,Breaking through the boundaries of traditional monitoring, providing a more convenient and comfortable wireless wearable experience for better treatment and faster recovery. Additionally,mWear also supportsHealth Parameter Monitoring and Patient Status Recognition.Relying on accurate monitoring of patient activity time and sleep time, assist medical staff in implementing ERAS, pain assessment, and prescribing sleep aids;Based on the recognition of falls, movement, sleep, and rest states, it assists medical staff in comprehensively understanding and evaluating the patient's rehabilitation status.

GE Healthcare and Masimo have long been partners, providing joint solutions to customers throughout the continuum of care. This time, the integration of Masimo's core technology with GE Healthcare’s latest product has added a unique "filter" to this collaboration. What technological achievements will both parties bring us in the future? Medical Device News will continue to follow.

END

Powerful Alliance! The Most Advanced Superconducting Heavy Ion Technology Enters China

How Should Endoscopy Companies Efficiently Empower Precision Medicine?

CIIE Review: Endoscopes + Surgical Robots

Asia-Pacific's First, "King of Rigid Endoscopes" Makes a Big Move

Giant in Vascular Interventions Announces Leadership Change

Innovative Medical "Black Tech", Boston Scientific Showcases Multiple Products at CIIE

Global First: Siemens Healthineers' 4D Volumetric Intracardiac Echocardiography Catheter Debuts at CIIE

Just now, the "MicroPort" two listed companies changed their leaders

Siemens Healthineers Unveils Multiple Groundbreaking New Products for the Sixth Consecutive Year at the CIIE

Breaking: Medtronic Partner May Be Delisted

BusinessBusiness cooperation email: qxzj@landianyiliao.com